Nurse-driven HFNC weaning protocol cuts therapy duration by 16 hours, hospital stay by 1 day in bronchiolitis infants
This prospective, randomized controlled trial evaluated whether a nurse-driven high-flow nasal cannula (HFNC) weaning protocol reduces HFNC duration and hospitalization in infants with severe bronchiolitis. The study was conducted in two tertiary pediatric intensive care units (PICUs) during a single bronchiolitis season. Infants aged 1-24 months requiring HFNC for severe bronchiolitis were randomized to standard care or a nurse-driven protocol group (n=55 per group, total n=110). The intervention involved structured assessments using the Wang Bronchiolitis Severity Score (WBSS) and the ROX index (SpO2/FiO2 divided by respiratory rate), with trained nurses initiating weaning based on predefined criteria. The primary outcome was total HFNC duration. Secondary outcomes included time to first weaning, PICU and hospital length of stay, need for non-invasive ventilation (NIV), intubation, readmission rates, nurse satisfaction, and protocol adherence. Results showed the nurse-driven group had a significantly shorter median HFNC duration (34.00 h vs. 50.00 h, p=.001) and earlier weaning initiation (12.00 h vs. 20.00 h, p<.001). PICU stay (3.00 vs. 4.00 days, p=.005) and hospital stay (6.00 vs. 7.00 days, p=.001) were also reduced. No significant differences were found in NIV use (p=.670), intubation (p=.450), or readmissions (p=.100). Nurse satisfaction with the protocol was 96.0%, and protocol adherence was 92.0%. The study concluded that a nurse-driven HFNC protocol is associated with reduced therapy duration and hospitalization in infants with bronchiolitis without increasing adverse outcomes. The trial was registered on ClinicalTrials.gov (NCT06621641) on November 22, 2025.